@transpread.bsky.socialA large prospective real-world study published in Cancer Biology & Medicine has confirmed that first-line osimertinib provides substantial clinical benefit to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
#Osimertinib
Details: doi.org/10.20892/j.i...
@newsen.bsky.socialIterion Therapeutics Unveils Groundbreaking Phase 1b Trial Data for Tegavivint and Osimertinib in Lung Cancer #United_States #Houston #Osimertinib #Iterion_Therapeutics #Tegavivint
@nikolospharma.bsky.social
@yalecancer.bsky.social#Osimertinib appears to ⬇️ the elevated brain metastasis risk historically associated with two common subtypes of EGFR mutations, supporting osimertinib's role as a preferred first-line treatment for EGFR-mutant #NSCLC.
medicine.yale.edu/cancer/publi...
@oncoalert.bsky.social
@medchemexpress.bsky.socialWCLC26 Highlights
🔹EGFR: Adjuvant #osimertinib → 74% 8-year OS in stage II-IIIA disease
🔹ROS1+: #Zidesamtinib → 94% response rate with strong intracranial activity
🔹HER2: T-DXd → improved PFS, but pulmonary safety remains a concern
🔹EGFR exon 20ins: #Amivantamab + chemotherapy → 34.3-month median OS
@newsen.bsky.socialLong-Term Benefits of Osimertinib in Resected EGFR-Mutated NSCLC Highlighted in ADAURA Trial Update #South_Korea #Seoul #NSCLC #Osimertinib #ADAURA
@rcatanho.bsky.socialOsimertinib más quimioterapia aumenta la supervivencia libre de progresión en pacientes con cáncer de pulmón no microcítico avanzado con mutación EGFR que portan mutaciones TP53 #NSCLC #osimertinib #mutations jamanetwork.com/journals/jam...